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Autosomal recessive Charcot-Marie-Tooth disease (CMT) type 4 (CMT4) is a complex group of demyelinating
hereditary motor and sensory neuropathies presenting genetic heterogeneity. Five different subtypes that correspond
to six different chromosomal locations have been described. We hereby report a large inbred Lebanese family
affected with autosomal recessive CMT4, in whom we have excluded linkage to the already-known loci. The results
of a genomewide search demonstrated linkage to a locus on chromosome 19q13.1-13.3, over an 8.5-cM interval
between markers D19S220 and D19S412. A maximum pairwise LOD score of 5.37 for marker D19S420, at
recombination fraction [v] .00, and a multipoint LOD score of 10.3 for marker D19S881, at , stronglyv = .00
supported linkage to this locus. Clinical features and the results of histopathologic studies confirm that the disease
affecting this family constitutes a previously unknown demyelinating autosomal recessive CMT subtype known as
“CMT4F.” The myelin-associated glycoprotein (MAG) gene, located on 19q13.1 and specifically expressed in the
CNS and the peripheral nervous system, was ruled out as being the gene responsible for this form of CMT.
Hereditary motor and sensory neuropathy (HMSN),
also known as “Charcot-Marie-Tooth disease” (CMT
[MIM 118300]), is a heterogeneous group of disorders
characterized by chronic distal weakness with progres-
sive muscular atrophy and sensory loss in the distal ex-
tremities (Dyck et al. 1993). With a frequency of ∼1/
2,500, CMT is the most common inherited neurological
disorder (Skre et al. 1974). Clinically, two major groups
are defined; they are differentiated on the basis of pe-
ripheral nerve pathology and the results of nerve con-
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duction velocity (NCV) studies. CMT type 1 (CMT1) is
characterized by low NCVs resulting from demyelina-
tion in the motor and sensory nerves, whereas CMT type
2 (CMT2) refers to neuropathies with normal NCVs and
no evidence of demyelination (Bell 1997). Modes of in-
heritance could be either autosomal dominant, autoso-
mal recessive, or X-linked. Autosomal recessive demy-
elinating CMT type 4 (CMT4) is less frequent and more
severe than the two other modes of inheritance. Five
different CMT4 subtypes, each of which presents par-
ticular ethnic, pathological, or clinical characteristics,
are known. They are CMT4A (MIM 214400) on 8q13-
21.1 (Ben Othmane et al. 1993); CMT4B, which in-
cludes CMT4B1 (MIM 601382) on 11q22 (Bolino et al.
1996), caused by mutations in the MTMR2 gene (MIM
603557) encoding myotubularin-related protein-2 (Bol-
ino et al. 2000), and CMT4B2 (MIM 604563) on 11p15
(Ben Othmane et al. 1999); CMT4C (MIM 601596) on
5q23-33 (Leguern et al. 1996); CMT4D (MIM 601455)
on 8q24 (Kalaydjieva et al. 1996); and CMT4E on
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Figure 1 Haplotype reconstruction in a Lebanese family affected with autosomal recessive demyelinating CMT at 19q13.1-13.3. Markers
are reported from centromere (top) to telomere (bottom). 1209C/T denotes a polymorphism in MAG. Blackened symbols represent affected
individuals. The disease-bearing chromosome is blackened. nt = not tested.
10q21-22. The fifth subtype, CMT4E, corresponds to a
congenital hypomyelinating neuropathy in which a ho-
mozygous missense mutation has been identified in an
early-growth-response gene (EGR2; Warner et al. 1998).
We now report the assignment of a new locus for an
autosomal recessive CMT4 subtype on chromosome
19q13.1-13.3 in a large inbred Lebanese family, using
homozygosity mapping (Lander and Botstein 1987) and
DNA pooling. The family presented with clinical fea-
tures that may define a new CMT4F subtype. Involve-
ment of the myelin-associated glycoprotein (MAG) gene,
which is located on 19q13.1 and is specifically expressed
in Schwann cells in the peripheral nervous system or in
oligodendrocytes in the CNS, was ruled out in this study.
Thirteen members of a Shiite Muslim family origi-
nating from a village in the south of Lebanon were in-
vestigated (fig. 1). All affected members, with the ex-
ception of patient VI-6, who was too young to present
all the clinical features, had nearly identical clinical, ra-
diological, and laboratory findings and were therefore
described together.
Gestation and delivery were unremarkable, with no
history of exposure to pre- or perinatal environmental
toxins in the family. All patients had a delay in motor
development. They started sitting by age 12–18 mo and
began walking and talking at age ∼2 years. From the
beginning, gait was described as wide-based and mildly
ataxic. At age 9–10 years, lower-limb distal muscle
weakness and atrophy with pes cavus deformity were
evident. By age 14–15 years, weakness of the upper
limbs—in particular, of the hands—and finger retraction
appeared. Upon examination, head circumferences and
statures were normal. The neurological examination
showed important sensory ataxia, bilateral steppage
gait, mild kyphoscoliosis, symmetrical atrophy of in-
trinsic hand muscles and of muscles below the knees,
pes cavus deformity, slightly diminished distal muscle
strength of the upper and lower limbs, with paresthesia
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Table 1
Pairwise LOD Scores between the CMT4F Locus and 11 Marker Loci on 19q13.1-13.3
MARKER
LOD SCORE AT v =
MAXIMUM
PAIRWISE
LOD SCORE MAXIMUM v.0001 .01 .05 .1 .2 .3 .4
D19S414  1.67 2.67 2.75 2.27 1.51 .69 2.77 .084
D19S220  3.12 3.41 3.20 2.42 1.49 .57 3.42 .043
D19S897 2.81 2.76 2.54 2.25 1.66 1.04 .47 2.81 .001
D19S881 5.14 5.04 4.63 4.09 2.99 1.84 .75 5.14 .001
D19S223 4.88 4.78 4.37 3.86 2.80 1.71 .65 4.88 .001
D19S872 .19 .18 .16 .12 .07 .03 .01 .19 .001
D19S211 .38 .37 .31 .25 .15 .07 .02 .38 .001
D19S420 5.37 5.26 4.83 4.28 3.12 1.92 .77 5.37 .001
D19S900 2.05 2.01 1.84 1.62 1.18 .75 .33 2.05 .001
D19S412  2.37 2.68 2.49 1.78 .92 .13 2.68 .045
D19S902  1.81 .08 .40 .46 .17 .06 .51 .154
on the distal portions of the lower limbs, absent osteo-
tendinous reflexes in four limbs, and distal sensory ab-
normalities—including deficits of position, vibration,
pain, and temperature—in both the upper and lower
extremities. No seizures, cranial nerve abnormalities, or
facial weakness were noted. Intelligence and speech were
normal. The progression of the disease had been very
slow. Only patient VI-7 could no longer walk, essential-
ly because of a severe left pes equinovarus. Total body
X-rays revealed the presence of scoliosis in all patients.
Magnetic-resonance imaging (MRI), which was per-
formed for patients VI-1 and VI-2, showed a large cis-
terna magna. The results of abdominal ultrasound, echo-
cardiography, and electroencephalography; evoked
potentials; auditory brain-stem responses; and the results
of ophthalmologic evaluation performed in some of the
patients were all unremarkable. The results of routine
laboratory tests as well as levels of plasma very-long-
chain fatty acids and results of white-blood-cell enzyme
assays were within the normal range. The karyotype was
normal (46,XY; patient VI-1). The results of NCV stud-
ies performed on five affected individuals revealed the
total absence of any sensory or motor evoked response
in the upper and lower limbs. Electromyograms (EMGs)
showed normal insertional activity, absence of sponta-
neous activity, and moderately reduced recruitment of
motor-unit potentials in the distal muscles of four limbs.
The results of EMG and NCV studies performed on
parents were completely normal.
Histopathologic examination of the whole sural
nerve–biopsy specimen from patient VI-1 disclosed a
severe depletion of myelinated fibers (estimated value
of density !1,000 fibers/mm2) and numerous extensive
concentric Schwann-cell proliferation with multiple
small onion bulbs isolated or surrounding the rare
remaining myelinated fibers. These data indicated a
severe axonal loss, following an initial process of
chronic demyelination-remyelination.
After familial investigations, EDTA blood samples
were collected for genetic studies. Informed consent was
obtained from all adults and from parents of children
included in the study. DNA was extracted from lym-
phocytes by use of standard methods (Miller et al. 1988).
A pooling strategy (for review, see Sheffield et al. [1995])
was used in the first genomewide screening. Three sep-
arate DNA pools—the “affected” pool, the “obligate-
carrier” pool, and the “unaffected” pool—were pre-
pared by mixing equimolar quantities of individual
DNAs. The screening set comprised 400 highly poly-
morphic fluorescently labeled markers from the ABI
PRISM Linkage Map Set, version 2.0 (PE Biosystems),
that had an average spacing of 10–20 cM and were
chosen from the Ge´ne´thon linkage map (Dib et al. 1996).
Amplifications were performed in a 7.5-ml final volume
on 40 ng pooled DNA. The cycling conditions used were
those recommended by the manufacturer (PE Biosys-
tems). Pooled PCR products were separated on a 5%
Long Ranger denaturing urea-polyacrylamide gel and
were analyzed on an ABI 377 DNA sequencer (PE Bios-
ystems). Peaks were analyzed with GENESCAN, version
3.1, and GENOTYPER, version 2.1 (PE Biosystems).
Several zones of homozygosity, which showed re-
duction to homozygosity in the affected pool, were
selected for genotyping of individual samples. Nev-
ertheless, only marker D19S420 (AFM326xh9) on
19q13.2 was found to be informative in the parents
and homozygous in all the affected individuals and
was selected for further genotyping. To determine the
size of the shared homozygous region, 10 new micro-
satellite markers surrounding D19S420 were selected
from the Ge´ne´thon human linkage map and were ge-
notyped in all individuals. Recombination events re-
stricted the homozygous candidate region to an 8.5-
cM interval distal to D19S220 (AFM214yf12) and
proximal to D19S412 (AFM284yg) (fig. 1).
Parametric linkage analysis was performed with an
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Figure 2 Multipoint LOD-score analysis of the CMT4F locus in the interval from D19S414 (centromeric) to D19S902 (telomeric). The
Y-axis represents the multipoint LOD score (log10 value), and the X-axis represents the genetic distance (in cM) along the interval.
optimized version of the LINKAGE package, version 5.2
(Lathrop et al. 1985). Pairwise LOD scores and multi-
point LOD scores were calculated using programs from
FASTLINK, version 3.0P. The disease was assumed to
be caused by a fully penetrant autosomal recessive gene
with a frequency of .002. Allele frequencies for micro-
satellite markers were chosen from the Genome Data-
base and were assumed to be the same as those defined
by Ge´ne´thon for the Caucasian population (Lefranc et
al. 1978).
A maximal pairwise LOD score of 5.37 was obtained
for D19S420 (table 1), and multipoint LOD-score anal-
ysis gave a maximum of 10.3 for D19S881, at v = .00
(fig. 2). Markers D19S872 and D19S211 showed poor
LOD-score values (table 1) as a result of their lack of
informativity. The other markers were informative in all
matings, and all affected individuals were homozygous
for the disease allele.
Of all the different genes already mapped to
19q13.1-13.3, the most likely candidate gene for this
particular form of CMT was the MAG gene on
19q13.1. Sequencing of its coding sequence was con-
sequently performed in two affected children (patients
VI-2 and VI-4) and a control individual. Total RNA
was extracted from lymphocytes by use of the total
RNA isolation kit (PROMEGA), and the MAG cDNA
was sequenced after reverse transcription (M-MLV
Reverse Transcriptase [Gibco BRL]) in illegitimate
transcripts (Chelly et al. 1991). Fragments used for
sequencing were obtained by means of a two-step PCR
amplification process using reverse-transcribed cDNA
as a template. However, as a result of the high GC
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Table 2
Primer Sequences for PCR Amplification and Sequencing of the MAG Coding Sequence
Reaction and Primer Sequence Position (5′)a
Amplification-
Product Size
(bp)
Annealing
Temperature
(C)
RTPCR1b:
1:
Forward: 5′-AGGTGCAGAAGCAACTGAGT-3′ 108 1,212 58
Reverse: 5′-CGTGGACAGGATCTGCTTCT-3′ 1225
2:
Forward: 5′-GGGACAATGGTGGCCGTA-3′ 996 1,084 64
Reverse: 5′-AAGGAGGTTAGAGAGGAGCC-3′ 2100
Nested PCR2sb:
1a:
Forward: 5′-ATGGTGCCGGACAACTGC-3′ 477 684 56
Reverse: 5′-GCTTCTCCTTGAAGATGGTGA-3′ 1090
2a:
Forward: 5′-GGGGGAGACGGTCTCTAT-3′ 1016 568 56
Reverse: 5′-GGCAATCAGGATGGCAAAGG-3′ 1584
2b:
Forward: 5′-TTCCAGGGAGCCCATCGA-3′ 1506 505 64
Reverse: 5′-CCTCACTGTCACCTGCCT-3′ 2011
2b′:
Forward: 5′-AGAAGTACGAGAGAGCGAGAGG-3′ 1705 305 60
Reverse: 5′-CCTCACTGTCACCTGCCT-3′ 2011
Genomic PCRsc:
Exon 4:
Forward: 5′-GTGTCACTGCATTCCAGCCC-3′ IVS3-207 375 56
Reverse: 5′-GTCCTACCCGATCACCCC-3′ IVS4120
Exon 5:
Forward: 5′-CTGAGCAGGTTGGAGGTGGG-3′ IVS4-117 578 66
Reverse: 5′-TGCTGGGGAAGGTGCGGG-3′ IVS592
Exon 6:
Forward: 5′-GGAGGCGATACCGTTGAGGAG-3′ IVS5-128 502 56
Reverse: 5′-CCGCATCCCCAGGTCCAC-3′ IVS677
Exon 7:
Forward: 5′-GACAGTGTTGGGGGCGGG-3′ IVS6-91 558 56
Reverse: 5′-AAGGAGGATGAGGCAGAGCAGCAGG-3′ IVS7208
a Numbering is according to the cDNA sequence published by Sato et al. (1989)
b Designed according to the cDNA sequences (GenBank accession number M29273).
c Designed according to the genomic DNA sequences (GenBank accession number AC002132).
content of the amplified products (55%–75%), am-
plification was obtained only when the PCRx En-
hancer System (Gibco BRL) was used, and the 5′ ex-
tremity of the cDNA fragment (684 bp) could not be
synthesized. Exons 5–7, which corresponded to the
unamplified 5′ cDNA sequence, were consequently
amplified from genomic DNA. PCR primers and an-
nealing conditions are described in table 2.
Amplification products were sequenced in both direc-
tions, with use of the Big Dye Terminator Cycle Se-
quencing Ready Reaction Kit (PE Biosystems) on an ABI
377 sequencer (PE Biosystems). Electrophoregrams were
analyzed using Sequence Analysis software, version 3.3
(PE Biosystems). Sequences were compared with refer-
ence sequences, by use of Sequence Navigator, version
1.0.1 (PE Biosystems). The reference sequences for
cDNA (GenBank accession number M29273) and ge-
nomic DNA (GenBank accession number AC002132)
were chosen from the GenBank sequence library.
The results of sequencing of the MAG coding region
in two affected patients and a control individual showed
neither a base change leading to an amino acid change
nor a deletion, but some discrepancies were observed
between the originally published cDNA sequence (Sato
et al. 1989) and the cDNA and genomic DNA sequences
used as references. A 399CrT change in exon 5, a
1140CrG change in exon 8, and a 1981CrG change
in the 3′ UTR region were not taken into consideration,
considering that 399T, 1140G, and 1981G were correct
in any of the three sequences. Finally, 1989insG was
observed in the 3′ UTR region in the affected patients
as well as in the control individual, suggesting a poly-
morphism or an error in the originally published cDNA
sequence. Alternative splicing of the 45-bp exon 12
Table 3
Major Clinical Features of Autosomal Recessive Demyelinating CMT4
CMT4 SUBTYPE
(LOCATION)
CLINICAL SIGNSa
MNCVb
(m/s) PATHOLOGICAL CHARACTERISTICScAge at Onset Muscle Weakness
Tendon
Reflexes Sensory Loss Disease Progression KS
Foot
Deformity
CMT4A (8q13-21) Early childhood Distal  Mild Incapacity, 1st decade   Reduced, ∼30 Hypomyelination; loss of MF; presence
of basal laminal onion bulbs
CMT4B1 (11q23) 2–4 years Distal and proximal  Moderate Death, 4th decade   Slow, 15–17 Loss of MF; presence of focally folded
myelin sheaths
CMT4B2 (11p15) !20 years Distal and proximal  Moderate Incapacity, 3d–4th decade   Reduced to slow,
15–30
Loss of MF; presence of focally folded
myelin sheaths
CMT4C (5q32) Childhood and
adolescence
Delayed walking Reduced Mild Increased disability   Reduced, ∼24 Loss of MF; presence of few classical on-
ion bulbs
CMT4D (8q24) Childhood Distal  Moderate, deafness Incapacity, 5th decade   Slow, 10–15 Loss of MF; presence of onion bulbs
CMT4E (10q21-22) Birth Distal  Moderate Increased disability   Slow, 9–20 Thin or absent myelin sheaths; presence of
onion bulbs
CMT4F (19q13.1-13.3) Early childhood Distal  Severe Slow progression   Not detectable Severe loss of MF; presence of onion bulbs
a A plus sign () denotes presence; a minus sign () denotes absence. KS = kyphoscoliosis.
b MNCV = motor NCV.
c MF = myelinated fibers.
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(GenBank accession number X98405) was observed in
the two affected patients as well as in the control indi-
vidual. A 1209C/T polymorphism was detected in pa-
tients VI-2 and VI-4 and in the control individual. Since
patient VI-4 was heterozygous for the polymorphism,
the affected sibs (patients VI-1, VI-3, and VI-6), the un-
affected brother (patient VI-5), and the parents (patients
V-1 and V-2) were also tested for the polymorphism.
The other branch of the family was not tested for this
polymorphism, since mRNA was not available. Patients
VI-1–VI-3 and patient VI-6 were homozygous for the
change, whereas the affected sister (patient VI-4), her
unaffected brother (patient VI-5), and the parents were
heterozygous for the change (fig. 1). Assuming identity
by descent and considering that patient VI-4 presented
a recombination at marker D19S220, we were able to
place MAG outside the homozygous candidate region
because of the heterozygosity for this polymorphism in
patient VI-4.
In the present study, we report a large inbred Leb-
anese family in whom affected members present the
heterogeneous neurological defects commonly seen in
autosomal recessive CMT4. Five pathological forms,
CMT4A–E, are now recognized (Ben Othmane et al.
1993; Bolino et al. 1996; Kalaydjieva et al. 1996; Le-
guern et al. 1996; Warner et al. 1998; Ben Othmane
et al. 1999). Clinical descriptions of these different
forms and of the form CMT4F presented here are
summarized in table 3. Although the clinical symp-
toms of the affected sibs in this report are similar to
—if somewhat more severe than—those in the other
forms of CMT4, there is enough genetic evidence to
suggest a new CMT4F subtype. Furthermore, the re-
sults of a genomewide search excluded linkage to
previously described autosomal recessive CMT4 loci
and placed the gene of interest distal to D19S220 and
proximal to D19S412, over an 8.5-cM interval at
19q13.1-13.3. The positive pairwise LOD score of
5.37 for D19S420, at , and the maximum mul-v = .00
tipoint LOD score of 10.3 for D19S881, at ,v = .00
strongly supported linkage of the disease gene to the
aforementioned region.
Of all the different genes already mapped to 19q13.1-
13.3, the most likely candidate gene for this particular
form of CMT was the MAG gene on 19q13.1. Indeed,
although the role of MAG in myelination is still unclear
(Attia et al. 1989; Li et al. 1994), its gene encodes a
transmembrane glycoprotein of the CNS and the pe-
ripheral nervous system that is thought to play a role in
the formation and maintenance of the myelin sheaths
(Quarles et al. 1983–84). Furthermore, the presence of
anti-MAG antibodies in the serum of patients affected
with some demyelinating sensory or sensorimotor neu-
ropathies and the overexpression of a shorter alterna-
tively spliced MAG mRNA in dysmyelinating mutant
mice have been reported (Frail et al. 1985; Sato et al.
1986). Nevertheless, none of the abnormalities usually
observed in nerve-biopsy specimens from mice, which
have a knocked-out MAG gene (Montag et al. 1994),
were observed in the nerve-biopsy specimen from patient
VI-1. Also, sequencing of the entire MAG gene-coding
region in two affected patients revealed neither a base
change nor a deletion, most probably excluding a point
mutation in the coding region as the cause of the disease.
Finally, heterozygosity for the 1209C/T polymorphism
in one of the affected children placed the MAG gene
outside the homozygous candidate region and definitely
excluded this gene as the gene responsible for the disease
(fig. 1).
Thus, refinement of the candidate interval and iden-
tification of the gene will need further investigations in
this family and in families presenting the same new
CMT4F subtype. Identification of the gene will improve
understanding of the pathogenesis of autosomal reces-
sive CMT4 disease.
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